The effect of subcutaneous injection duration on patients receiving low-molecular-weight heparin: Evidence from a systematic review  by Yi, Li-juan et al.
w.sciencedirect.com
i n t e r n a t i o n a l j o u r n a l o f nu r s i n g s c i e n c e s 3 ( 2 0 1 6 ) 7 9e8 8HOSTED BY Available online at wwScienceDirect
journal homepage: ht tp: / /www.elsevier .com/journals / internat ional -
journal -of -nursing-sciences/2352-0132Original ArticleThe effect of subcutaneous injection duration on
patients receiving low-molecular-weight heparin:
Evidence from a systematic reviewLi-juan Yi a,1, Ting Shuai a,1, Xu Tian a,1, Zi Zeng a, Li Ma a,
Guo-min Song b,*
a Master degree candidate, Graduate College, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193,
China
b Director of Nursing, Nursing Department of Tianjin Hospital, Tianjin 400020, Chinaa r t i c l e i n f o
Article history:
Received 26 September 2015
Received in revised form
20 November 2015
Accepted 2 February 2016
Available online 16 April 2016
Keywords:
Heparin
Injections,subcutaneous
Injection duration
Systematic review
Meta-analysisAbbreviations: SC, subcutaneous; LWMH,
and Meta-analysis; JBI-MASTARI, Joanna Br
risk; MD, mean difference; RCTs, randomize
* Corresponding author.
E-mail address: songguomin134@163.com
Peer review under responsibility of Chinese
1 These authors have contributed equally
http://dx.doi.org/10.1016/j.ijnss.2016.02.008
2352-0132/Copyright © 2016, Chinese Nursin
the CC BY-NC-ND license (http://creativecoma b s t r a c t
To assess the effect of the injection duration of subcutaneous low-molecular-weight heparin
(LMWH) on pain and bruising in patients. Randomized controlled trials and quasi-
experimental studies were searched for in four electronic databases. The pooled effect size
wasexpressedas relative risk (RR) andmeandifference (MD)with95%confidence intervals (CI)
for dichotomous and continuous data. Cochrane Q and p value were used to assess hetero-
geneity and the I2 statistic was adopted to quantify the level. Finally, eight studies involving a
total of 532 participants met our inclusion criteria. The slow (30 second) injection was asso-
ciatedwith a reduction in pain intensity and duration, and lower bruising occurrence at 48e72
hours and 48 hours post injection. The bruising areawas also smaller at 48 hours and 60 hours
post injection.Nodifferenceswere identifiedbetween the slowand fast (10 second) injection in
bruising area and bruising occurrence at 24 hours and 60 hours post injection. With present
evidences, slow injection of LMWH is beneficial to the patient's well being, but further studies
to identify the feasibility and standardization of the technique is recommended.
Copyright © 2016, Chinese Nursing Association. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).especially those administrated via subcutaneous (SC), in-
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Pharmaceutical administration is an extremely important
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iggs Institute Meta-Analy
d controlled trials.
(G.-m. Song).
Nursing Association.
to this article.
g Association. Production
mons.org/licenses/by-nctradermal or intramuscular, put extra responsibilities on
nurses to explore safe and standard injection techniques to
minimize unnecessary pain and potential complications
[1,2].parin; PRISMA, Preferred Reporting Items for Systematic Reviews
sis of Statistics Assessment and Review Instrument; RR, relative
and hosting by Elsevier B.V. This is an open access article under
-nd/4.0/).
i n t e r n a t i o n a l j o u rn a l o f n u r s i n g s c i e n c e s 3 ( 2 0 1 6 ) 7 9e8 880As a type of heparin, low molecular weight heparin
(LMWH) is only administered subcutaneously [3]. LMWH is
frequently prescribed for preventing or treating venous
thromboembolism because of its high bio-availability and
predictable anticoagulant effect [4,5]. However, just like any
other drugs, the use of LMWH does not come without possible
adverse reactions. SC heparin preparations often cause
adverse effects (AEs) such as bruising, pain, induration and
hematoma at the injection site [6,7]. In this regard, previous
study has indicated that these local complications increased
the patients physical and psychological discomfort and thus
resulted in patients' distrust in nurses' efficiency [8,9]. In
addition, the bruising can also restrict the possible area for
future SC injection and reduce the opportunities for site
rotation [10,11].
Literature related to the SC heparin injection have
explored the potential factors which might minimize those
side reactions and considered that the selection of syringe
size and injection site, the application of ice and aspiration,
and the injection duration can impact the occurrence of
bruising and pain [12e15]. Among them, injection duration
is an important influence factor. The researchers recom-
mended giving SC LMWH injections over a 10-s duration
[11,12], but which injection duration technique is ideal is far
from clear.
Several Studies [16,17] previously have investigated the
effects of injection duration on adverse outcomes at the in-
jection site associated with SC administration of LMWH.
Although exhaustive association trials have been undertaken
to settle this issue, it hasn't yet been obtained a definitive
conclusion, and those results haven't been recur. To provide
more information for nursing practice, this systematic review
examines existing knowledge to objectively assess the influ-
ence of two different injection techniques (10-s versus 30-s) on
pain and bruising at the injection site in hospitalized patients
who require LMWH therapy.2. Material and methods
The Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) Statement [18] and Cochrane Hand-
book for Systematic Reviews of Interventions were adopted to
guide the systematic review andmeta-analysis [19]. All pooled
analyses were grounded on previously published literature,
and thus no ethical approval and patient informed consent
were required.
2.1. Inclusion and exclusion criteria
We pre-specified the inclusion criteria for our study ac-
cording to the PICOS format (which describes the partici-
pants, intervention, comparison, outcomes and study
design). The details of this criterion were as following: (1) P:
participants were considered meet the inclusion criteria if
they were (a) 18 years or older; (b) administered LMWH
therapy subcutaneously in hospital. (2) I and C: Two tech-
niques of 30-s SC administration of LMWH in the one site of
the abdomen as the intervention and 10-s SC administration
of LMWH in the other site of the abdomen as the controlwere performed. (3) O: the pain intensity, the incidence of
bruising and the size of bruising at the injection site were
listed to be as primary outcome of measures and bruising
dimensions and the site-pain duration were viewed as sec-
ondary outcomes. (4) S: Randomized controlled trials (RCTs)
and quasi-experimental methodology would be appraised
and included in the review.
It was ineligible for the study if the patients were currently
on any other anticoagulant therapy. Study without a com-
parison group were excluded. Language of publication was
imposed into English or Chinese through August, 2015.2.2. Search strategies
We searched PubMed, EMBASE, the Cochrane Library, and the
China National Knowledge Infrastructure (CNKI) to collect
potential relevant randomized controlled trials (RCTs) and
quasi-experimental studies through August, 2015. The search
strategies utilized are shown in Appendix A. Next, the refer-
ence lists of included articles were manually searched to
include any eligible studies.2.3. Data abstraction
Two investigators (L-JY and TS) independently extracted the
following basic information and essential continuous and bi-
nary data for expected outcome of interest from each included
study using the predesigned data extraction form (Table 1):
study ID which included first author and publication year,
country, number of participants, demographics of subjects
(age and gender), intervention, reported outcome of interest.
The author would be contacted to acquire the complete data
when necessary. If researchers provided inconsistent data for
same outcome, we would obtain the most rational one. Any
divergences between authors concerning the eligibility of a
study were resolved by consulting a third author until a
consensus was obtained (XT).2.4. Quality appraisal
Risk of bias was assessed for RCTs using the Cochrane Risk of
Bias Assessment tool (19) and for quasi-experimental study
using the Joanna Briggs Institute Meta-Analysis of Statistics
Assessment and Review Instrument (JBI-MASTARI) (see
Appendix B) independently by two investigators (ZZ and LM).
Disagreement was resolved by consulting a third investigator
(G-MS). The Cochrane Risk of Bias Assessment tool addresses
six specific domains as follows: sequence generation, alloca-
tion concealment, blinding, incomplete outcome data, selec-
tive outcome reporting, and other issues. The risk of each
included study was rated as ‘low bias risk’, ‘unclear bias risk’
or ‘high bias risk’ in accordance with the adequate degree of
information extracted. The JBI-MASTARI tool based upon a
quantity of critical questions fastened on the aspects of study
design that research has shown to affect significantly the
validity, for example, randomization, allocation, blinding and
reporting. Each study was thus evaluated for quality utilizing
the below checklist.
Table 1 e Characteristics of included trials
Author
(publication
year)
Country Target disease Injection protocol Age (E/C) Sex
(male/female)
Interventions Outcome
Slow injection group (E) Fast injection group (C)
Zaybak A (2006) Turkey Cardiovascular
disease, fractures,
stroke
Insertion angle 90; injection
without drug aspiration;
interval: 12h;
55.52 ± 12.37 25/25 Heparin was injected over
30 seconds on the left or
right side of the abdomen
Heparin was injected over
10 seconds on the other side
of the abdomen
a þ b þ c þ e þ f
Sendir M (2015) Turkey Total hip
arthroplasty, total
knee arthroplasty
Insertion angle 90; injection
without drug aspiration;
interval: 24h;
62.7 ± 8.83/57.9
± 12.5
E: 7/13
C: 6/14
Heparin was injected over
30 seconds on the one side
of the abdomen
Heparin was injected over
10 seconds on the other side
of the abdomen
a þ b þ d
Dehghani K (2014) Iran Acute coronary
syndrome
Insertion angle 90; injection
with drug aspiration; interval:
12h; drug dose: 60e80 mg
Enoxaparin
35e75 36/34 Heparin was injected over
30 seconds on the left or
right side of the abdomen
Heparin was injected over
10 seconds on the other side
of the abdomen
c þ e
Dadaeen A (2015) Iran Cardiology,
neurology,
orthopedic
Insertion angle 90; 27 gage
needle; injection without drug
aspiration; interval: 12/24 h;
drug dose: 40 mg with volume
of 0.4 mL or 60 mg with volume
of 0.6 mL Enoxaparin; air lock:
0.2 mL inserted
47.78 ± 20.19 70/30 Heparin was injected over
30 seconds on the right side
of the abdomen
Heparin was injected over
10 seconds on the left side
of the abdomen
a þ c þ e
Palese A (2013) Italy Unclear Insertion angle 90; 27.5 gage
needle; syringe volume
(0.4 mL); injection with drug
aspiration; interval: 24h; drug
dose: 4000 IU/0.4 mL
Enoxaparin
74.8 ± 15.5 48/102 Heparin was injected over
30 seconds on the right side
of the abdomen
Heparin was injected over
10 seconds on the left side
of the abdomen
b þ d
Deng QX (2009) China Myocardial
infarction, deep
venous thrombosis,
cerebral thrombosis
angina
Insertion angle 90; interval: 12
drug dose: 0.4 mL LMWH
57.6 ± 9.6 29/23 Heparin was injected over
30 seconds on the left side
of the abdomen
Heparin was injected over
10 seconds on the right side
of the abdomen
a þ b þ c
Balci AR (2008) Turkey Chronic obstructive
lung disease
Insertion angle 90; 27 gage
needle; injection without drug
aspiration; interval: 24 h; drug
dose: 4500 IU/0.45 mL
Tinzaparin; air lock: 0.2 mL
inserted
60.02 ± 11.77 23/13 The second morning
heparin was injected over
10 seconds on the left
abdominal site
The first morning heparin
was injected over 10
seconds on the right
abdominal site
b þ d þ e
Chan H (2001) Australia Stroke Insertion angle 90; 27.5 gage
needle; syringe volume
(0.5 mL); injection without drug
aspiration; interval: 12 h; drug
dose: 5000 IU/0.2 mL
Dalteparin; use air lock
40e85 20/14 Heparin was injected over
30 seconds on the left or
right side of the abdomen
Heparin was injected over
10 seconds on the other side
of the abdomen
a þ b þ c þ d þ e
a ¼ pain intensity; b ¼ incidence of bruising; c ¼ size of bruising; d ¼ bruising dimensions; e ¼ range of bruising size; f ¼ pain duration.
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The pain intensity and pain duration, the incidence, size
and dimension of bruising at the injection site were calcu-
lated. Heterogeneity was evaluated using the Chi2, corre-
sponding P value. The level of heterogeneity was quantified
by using I2 statistic. If I2 was 50%, the eligible study was
considered to be heterogeneity and a random-effects model
was conducted. In contrary, a fixed-effect model was per-
formed. The pooled effect size was expressed as relative risk
(RR) and mean difference (MD) with 95% confidence in-
tervals (CI) for dichotomous and continuous data, respec-
tively. A two-side P value of 0.05 indicates statistical
significance. The descriptive analysis was adopted to
objectively present the results across eligible study in terms
of outcomes of interest which were ineligible for quantita-
tive analysis. Considering different types of studies exist
different risk of bias and measures of effect, We attempted
to combine evidence respectively for RCTs and quasi-
experimental studies. All pooled analyses were performed
using Review Manager (RevMan) 5.3.0 (the Cochrane
Collaboration, Copenhagen, Denmark).3. Results
3.1. Search outcome
The search initially yielded 952 records. After screening title,
abstract and full-text, a total of 8 studies were eligible for in-
clusion in the review. Among these trials, 5 were RCTs
[2,4,8,20,21] and three were quasi-experimental non-ran-
domized studies [7,9,22] (see Fig. 1). The full texts of these
articles were obtained for analysis.3.2. Characteristics of included trials
Seven articles [2,4,7e9,20,21] were published in English and
one [22] in Chinese, and a total of 532 participants were
included. The characteristics of 8 publications were
abstracted and assessed (see Table 1).3.3. Assessment of risk of bias
We presented an assessment of the methodological quality
using Cochrane Collaboration's tool for the five RCTs (see
Table 2). Additionally, we critically applied the JBI-MAStARI
tool for appraising the quality of incorporated quasi-
experimental studies (see Table 3). Risk of bias for the five
RCTs was discussed under the subheadings below.
3.3.1. Random sequence generation
Most randomized clinical trials lacked the description of the
randomization process. All studies appeared to be random-
ized, but there was only one studies [2] for which the method
of sequence generation could be confirmed in sufficient detail
to ascertain true randomization. So only one studywas judged
to be at low risk of bias and four studies at unclear risk of bias
for this domain.3.3.2. Allocation concealment
Only one study [21] was deemed to report allocation
concealment adequately, so it is judged as being at low for risk
of bias. For the rest of studies, method not stated, so they are
judged at unclear risk of bias in this domain.
3.3.3. Blinding
Most of included studies [4,8,20,21] used a design with the
subjects as their own control. It was hard to envisage how
blinding of subjects could be applicable, because every
participant had both slow and fast injections techniques,
during the period of the study, participants would know
which programs not be experienced. Because evaluation of
the pain intensity mainly depended on the subjective
judgment of participants, it could influence the outcomes
in a large extent for whether implement blinding for par-
ticipants. Meanwhile, it was also impossible to blind the
personnel owing to the nature of intervention. Further-
more, only blinding of outcome assessment could be
completed in these trials, two studies [4,21] not reported
assessor blinding for pain evaluation, and one study [8] not
reported assessor blinding for bruising measurement, ac-
cording to the outcomes they reported, the domain of two
articles were regarded as “unclear risk” and one as “low
risk”. Other two studies [2,20] stated all injections and post-
injection measurements were conducted by same
researcher for both group, which produced high perfor-
mance and detection bias. They were regarded as “high
risk” in this domain.
3.3.4. Incomplete outcome data
There was no drop-outs or losses to follow up. Therefore, they
were considered to be at low risk of attrition bias for this
domain.
3.3.5. Selective report
All trials adequately reported all expected measure outcomes
of interest in the paper and were deemed to be at low risk of
bias.
3.3.6. Other potential source of bias
All studies were funded by non-commercial organizations.
However, the description about other aspects of heparin in-
jection was scarce, such as amount of heparin, syringe size,
needle gage and injection volume. These factors may have an
potential effect to the outcomes. To assess potential publica-
tion bias, we planned to perform a funnel plot and assess it
asymmetry visually, however, only five studies included in
this meta-analysis, it was not appropriate owing to lack of
detecting power.3.4. Intervention effects
3.4.1. Pain intensity
A total of 5 reports [2,4,7,8,22] including 3 RCTs and 2 quasi-
experimental trials investigated the site-pain intensity. Pain
assessment was performed immediately after each injection.
Among them, Dadaeen et al. [4] applied Wilcoxon non-
parametric test to compare pain severity between the two
Studies included in quantitative
synthesis (n=8)
Studies included in qualitative
synthesis (n=8)
Records screened (n=953) Records excluded on review 
of abstract (n=934)
Records after duplicates removed (n=286)
Database searched using the 
designated keywords: (n =1239)
PubMed (n=409)
the Cochrane Library (n=355)
EMBASE (n=373)
CNKI (n=102)
Additional records identified
through other sources (n=1)
Full-text articles assessed for
eligibility (n=19)
Full-text articles excluded (n = 11)
Review (n=1)
Unrelated to intervention (n=7)
Participants used anticoagulant drugs (n=3)
Fig. 1 e PRISMA flow diagram of retrieval and selection of literature.
Table 2 e Risk of bias in randomized control trials
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7
Dadaeen A (2015) U U H U L L U
Dehghani K (2014) U U H H L L U
Palese A (2013) U L L L L L U
Sendir M (2015) L U H U L H U
Zaybak A (2006) U U H U L L U
Q1 ¼ random sequence; Q2 ¼ allocation concealment;
Q3 ¼ blinding of participants and personnel; Q4 ¼ blinding of
outcome assessment; Q5 ¼ incomplete outcome data;
Q6¼ selective reporting; Q7¼ other bias; H¼high bias; L¼ low bias;
U ¼ unclear bias.
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[2,8] and two quasi-experimental studies [7,22] were quantita-
tively synthesized with clinical and statistical homogeneity in
the pain intensity, respectively. (RCTs: P ¼ 0.34, I2 ¼ 0%; quasi-
experimental studies: P ¼ 0.49, I2 ¼ 0%), and thus a fixed-effect
model of analysis were used. The treatment effects signifi-
cantly differed between the two groups (RCTs:MD¼3.05, 95%
CI: 5.02, 1.08, P ¼ 0.002; quasi-experimental studies:Table 3 e Risk of bias in quasi-experimental studies
Study Q1 Q2 Q3 Q4
Deng QX (2009) NA NA U Y
Balci AR (2008) NA NA U Y
Chan H (2001) NA NA U Y
Y ¼ Yes; N ¼ No; U ¼ Unclear; NA ¼ Not Applicable; See Appendix B for qMD ¼ 8.73, 95% CI: 11.23, 6.24, P < 0.000) (Fig. 2A, B). More-
over, Dadaeen et al. (4) used the Numeric Rating Scale to mea-
sure pain intensity, and the results showed the median and
interquartile range of pain intensity scores in 10- and 30-
s injection were 5 (4e7) and 3 (1.25e5), respectively, (p < 0.001).
3.4.2. Incidence of bruising
Six studies [2,7e9,21,22] which included 3 RCTs and 3 quasi-
experimental studies employed the incidence of bruising as
outcome. No overall heterogeneity for polled existed in both
types of studies (RCTs: P ¼ 0.48, I2 ¼ 0%; quasi-experimental
studies: P ¼ 0.65, I2 ¼ 0%). On completion of the intervention
period, the slow injection reduced the risk of occurring a
bruising by 43% and 40%, severally. Subgroup analysis which
was conducted on the basis of evaluating time demonstrated
that the 30-s injectionwasmore effective than 10-s injection in
reducing the bruising occurrence (48e72 hours e RCTs:
RR¼ 0.63, 95% CI: 0.46, 0.87, P¼ 0.006; 48 hours-RCTs: RR¼ 0.53,
95% CI: 0.36, 0.77, P ¼ 0.00; 48 hours-quasi-experimental
studies: RR ¼ 0.60, 95% CI: 0.45, 0.81, P ¼ 0.00; 48e72 hours-
quasi-experimental studies: RR ¼ 0.63, 95% CI: 0.42, 0.94,
P ¼ 0.02) except in 60 hours after injection (quasi-experimental
studies: RR ¼ 0.56, 95% CI: 0.30, 1.02, P ¼ 0.06) (Fig. 3A, B).Q5 Q6 Q7 Q8 Q9 Q10
U Y Y Y Y Y
Y Y Y Y Y Y
U Y Y Y Y Y
uestion list.
AB
Fig. 2 e A) Meta-analyses for pain intensity (RCTs). Meta-analysis fixed-effects estimates were used. B) Meta-analyses for
pain intensity (quasi-experimental studies). Meta-analysis fixed-effects estimates were used.
B
A
Fig. 3 e A) Meta-analysis for incidence of bruising (RCTs). Meta-analysis fixed-effects estimates were used. B) Meta-analysis
for incidence of bruising (quasi-experimental studies). Meta-analysis fixed-effects estimates were used.
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A total of 6 articles [2,4,7,8,20,22] which divided into 4 RCTs
and 2 quasi-experimental studies reported the bruising area.
The bruising area was marked on a transparent measuring
paper or talc and calculated in mm2. Among them, Sendir
et al. [2] used a completely different method to measure the
surface area of bruise tracings, this heterogeneity might
reduce the comparability of the available results, and thus we
only made a description for it.
Sub-group analysis was conducted due to the different
follow-up. For three RCTs [4,8,20], pooled result revealed slow
injectionhassmaller sizeof bruises comparedwith fast injection
at 48h follow-up (48 hours: MD¼ 21.79, 95% CI:23.77,19.82,
P<0.000).However,nodifferencewas identifiedbetweenthetwo
techniques at both 24 and 72 hours follow-up (24 hours:
MD¼18.71, 95%CI:18.67, 56.09, P¼0.33; 72hours:MD¼88.40,
95% CI:22.16, 44.36, P ¼ 0.19) (Fig. 4). Sendir et al. [2] concluded
that an SC injection duration of 30 seconds can result in signifi-
cantly smaller bruises at 48, 60 and 72 hours after injection. For
two quasi-experimental studies [7,22], considering the different
injection protocols (drugs, doses and intervals) adopted,we only
madeanarrativeanalysis.Chanetal. [7]demonstratedthat there
was significantly difference between two techniques at both 48
hours (Z¼4.542, P¼ 0.000) and 60 hours (Z¼4.569, P¼ 0.000)
after each injection. The obtained results conducted by Deng
et al. [22] showed the bruise was of bigger size in fast injection
technique compare to slow injection technique at both 48 hours
(P¼ 0.008) and 72 hours (P¼ 0.016) post injection. The conflicting
conclusions is likely, whereas, to ascribable to the inappropriate
timing of bruise data collection. According to the evidence
available, the bruising usually peaks at 48 hours and tends to
resolution around 72 hours after the use of LMWH [23,24].
3.4.4. Bruising dimension
One RCT [21] and one quasi-experimental study [9] were
involved in this indicator. As the difference of studies types
exist, we only made a descriptive analysis. Balci et al. [9]
considered the slow injection has larger bruises than the
fast injection at 48 hours after injection (P ¼ 0.000), but Palese
et al. [21] found no difference in average bruising dimension
between treatments at the same time (P ¼ 0.661). ThisFig. 4 e Meta-analysis for bruising area (RCTs). Meinconsistency caused by the various measurement methods
was used to measure diameter extension. The former
measured the maximum dimensions only when the shape is
irregular, however, the latter recorded the maximum dimen-
sion of the bruise whether the shape is regular or not.
3.4.5. Pain duration
One RCT [8] and one quasi-experimental study [22] employed
the pain duration as outcomes. To determine this outcome,
the patients were asked to state the start and end values of
their pain. As studies types differ, we only made a qualitative
analysis. Both studies demonstrated pain period was short-
ened following the 30-s injections compared with 10-
s injections (P ¼ 0.000 and P ¼ 0.030, respectively).4. Discuss
4.1. Necessity
The SC administration of the anticoagulant LMWH is a regu-
larly performed nursing intervention. Since LWMH inhibit
blood coagulation and needle punctures injury the skin tissue
[1,25], thus it tends to cause bruising and pain at the injection
site. Epidemiology indicates the incidence levels of local
bruising vary considerably, range from 20.6% to 88.9% after
LMWHadministration [7,9].With a view to easing the pain and
improving patients' satisfaction, it is incumbent upon health
care professional to investigate the most appropriate SC
administration technique of LMWH by manipulated control-
ling factors. From the physiological perspective, adminis-
trating an injection slowly can reduce pain and bruising
caused by increased tissue pressure trauma [26]. However, the
application of the injection duration not yet formed unified
regulations so far.
4.2. Summary of main results
Take into account a short of data from only RCTs; we widened
our inclusion criteria from RCTs and quasi-experimental
studies to make an attempt to increase the number ofta-analysis fixed-effects estimates were used.
i n t e r n a t i o n a l j o u rn a l o f n u r s i n g s c i e n c e s 3 ( 2 0 1 6 ) 7 9e8 886available information. Eventually, Five RCTs and three quasi-
experimental studies met our inclusion criteria. This meta-
analysis found evidence that the slow injection technique
could effectively improve pain intensity and pain period
measured over time and decrease bruising occurrence at both
48e72 and 48 hours follow-up and the bruising size at both 48
and 60 hours follow-up compare to the fast injection tech-
nique. But no difference was identified in bruising area and
bruising occurrence between groups measured at 24 and 60
hours follow-up. Furthermore, due to insufficient data, we
cannot draw a reliable conclusion of whether the slow injec-
tion technique can reduce the bruising area at 72 hours follow-
up and bruising dimension at 48 hours follow-up.
4.3. Mechanism
Possibleexplanations thatwhyslow injection techniquemaybe
effective in pain and bruising are explored: a) SCadministration
delivers the LMWH into the interstitial space of the hypodermis
whichcontains fewarterioles andvenues, and thusunabsorbed
drugs concentrated the injection site [27]. Slow injection can
accelerating drug absorption, reducing tissue stimulation and
damage at the injection site [28,29]; b) A fast injection technique
cause tissue damage due to the rising strength giving to the
tissue, while slow injection allowmore time for the SC tissue to
accommodate the drug, lowering the tissue pressure in the
puncture site, and thus result in less nerve fiber endings and
tissue injury frommechanical trauma [15,30].
4.4. Limitation
Weperformed this systematic reviewtogeneratemoreaccurate
results based on enlarged the cumulative sample size, several
limitations were need to be acknowledged. Firstly, incomplete
search and the restriction of the language can reduce power of
pooled results. Secondly, the subjects of included studies suf-
fered different diseases would limit the generalization of evi-
dence. It should be considered adjust the injection period
appropriately to accommodate different groups. Third, scarce
articles provided a detailed description about whether patients
were taking the analgesicmedications in process of research, it
is an undeniable fact that the usage of analgesic medications
affected the assessment of the pain. Except that, injection
technique for participants should be more standardized and
systematic. We discovered from injection protocol that it still
not formed a consensus in the selection of gage needle, the
application of aspiration and air lock. These factorsmay impair
the heterogeneity among these studies. Sowe hope researchers
do more studies to provide more standardized, scientific and
rationalized way for clinical use.
4.5. Implications for practice and research
The current research provides a contribution to the precau-
tion of local complications associated with SC administration
of LMWH. Though ice application has already been proved
effective in reducing site-pain [6,10], however, it requires
additional nursing time and effort. Besides, the use of a larger
syringe or a higher gage needle can also result in less tissue
pressure trauma [12,31], but it is costly and waste limitedresources. Comparing these methods above, slow injection
technique may be more practical for nurses.
But there are some issues to think and tackle. Firstly, it is
worth considering the feasibility of the technique. Adminis-
trating a solution of less than 1 ml in 30 seconds is difficult,
especially when assisting confused patients. Other research
models that investigate the effect of intermediate injection
duration (that is 15 and 20 seconds) for developing new in-
terventions preventing local reactions related to LMWH are
strongly recommended. Secondly, the extension of operation
time need nurses focus more on keeping warm and protecting
privacy of patients. Meanwhile, the studies which use to eval-
uate the different SC injection sites for LMWH therapy are
needed. At present, it is only recommended that injections sites
should have a sufficient amount of fat [32], however, whether
the abdomen is the only or preferred site for SC injection is still
unclear [13,33,34]. Except that, further studies need to pay
attention to other outcomes, such as leakage of drugs and he-
matomaat the injection site.No included studies reported these
indicators,but theseoutcomeshavegreatvalue forassessingthe
effectofslowinjectionandworthto investigate infuturestudies.5. Conclusions
Although some limitations may impair the power of this
study, we concluded that slow injection can alleviate site-
pain, reduce pain time, bruising occurrence and decrease
the bruising size as a whole except some slight fluctuations
following the measuring time. Thus the clinical practice of
utilizing the slow injection as a proper method for SC LMWH
injections was supported. In consideration of chance error,
more large-scale and design-well prospective studies are
warranted to further this conclusion.Authors' Contributions
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